Niagen Bioscience: A Breakout Quarter That Now Faces Its Biggest Market Shift In Years
Stock Analysis, Healthcare, Life Sciences Tools and Services Alexander I. Velasquez Stock Analysis, Healthcare, Life Sciences Tools and Services Alexander I. Velasquez

Niagen Bioscience: A Breakout Quarter That Now Faces Its Biggest Market Shift In Years

Niagen Bioscience (NASDAQ:NAGE) Q3 2025 earnings delivered explosive growth in revenue, margins, and cash flow—just as NMN re-enters the NAD+ market. Here’s what investors need to know about this new competitive pressure.

Read More
Nintendo: Earnings Show Switch 2 Demand Surging As Margin Recovery Becomes The Next Test

Nintendo: Earnings Show Switch 2 Demand Surging As Margin Recovery Becomes The Next Test

Nintendo’s (OTCPK:NTDOY) Switch 2 launch has shattered records with 10.36 million units sold, driving sales but pressuring margins. My analysis breaks down why upcoming titles like Pokémon Legends Z-A and Metroid Prime 4 could spark the company’s next profit surge.

Read More
CD Projekt Vs. Square Enix: One Valued For Diversification And Catalysts, The Other Priced For 2027

CD Projekt Vs. Square Enix: One Valued For Diversification And Catalysts, The Other Priced For 2027

Square Enix (OTCMKTS:SQNNY) trades at just 16× EV/EBITDA versus CD Projekt’s (OTCMKTS:OTGLY) 54×, offering stronger value, diversified revenue, and near-term catalysts. My analysis compares both gaming stocks to reveal why Square Enix’s disciplined reinvestment and efficient growth make it the smarter pick heading into 2026.

Read More